期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 9, 期 12, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a036293
关键词
-
资金
- Ministerio de Economia y Competitividad (Spain) [SAF2013-48812-R, SAF201679847-R]
- Ministerio de Economia y Competitividad (Fondo Europeo de Desarrollo Regional) [SAF2013-48812-R, SAF201679847-R]
- Gobierno Vasco, Departamento de Salud (Basque Country, Spain) [2013111011]
- Norwegian Research Council, Norway [239813]
- Gobierno Vasco, Departamento de Educacion (Basque Country, Spain) [PRE_2014_1_285]
- Asociacion Espanola Contra el Cancer (AECC, Junta Provincial de Bizkaia, Spain)
- Ikerbasque, the Basque Foundation for Science
PTEN is a major tumor-suppressor protein whose expression and biological activity are frequently diminished in sporadic or inherited cancers. PTEN gene deletion or loss-of-function mutations favor tumor cell growth and are commonly found in clinical practice. In addition, diminished PTEN protein expression is also frequently observed in tumor samples from cancer patients in the absence of PTEN gene alterations. This makes PTEN protein levels a potential biomarker parameter in clinical oncology, which can guide therapeutic decisions. The specific detection of PTEN protein can be achieved by using highly defined anti-PTEN monoclonal antibodies (mAbs), characterized with precision in terms of sensitivity for the detection technique, specificity for PTEN binding, and constraints of epitope recognition. This is especially relevant taking into consideration that PTEN is highly targeted by mutations and posttranslational modifications, and different PTEN protein isoforms exist. The precise characterization of anti-PTEN mAb reactivity is an important step in the validation of these reagents as diagnostic and prognostic tools in clinical oncology, including their routine use in analytical immunohistochemistry (IHC). Here, we review the current status on the use of well-defined anti-PTEN mAbs for PTEN immunodetection in the clinical context and discuss their potential usefulness and limitations for a more precise cancer diagnosis and patient benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据